Ilunocitinib

Last updated

Ilunocitinib
Ilunocitinib.svg
Clinical data
Trade names Zenrelia
Other namesLY-3411067
License data
Routes of
administration 		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C17H17N7O2S
Molar mass 383.43 g·mol−1
3D model (JSmol)
  • C1CC1S(=O)(=O)N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4
  • InChI=InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)
  • Key:RVOUEXFKIYNODQ-UHFFFAOYSA-N

Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs. [1] [3] It is a non-selective janus kinase inhibitor. [3]

Contents

Ilunocitinib was approved for medical use in the United States in September 2024, [4] and in Canada in December 2024. [1]

Medical uses

Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age. [1] [3] [5]

Contraindications

It is not safe to administer vaccines to dogs that are concurrently receiving ilunocitinib. [5]

Society and culture

Ilunocitinib was approved for medical use in the United States in September 2024, [6] and in Canada in December 2024. [1]

In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Zenrelia, film-coated tablets, intended for dogs. [7] The applicant for this veterinary medicinal product is Elanco GmbH. [7]

Names

Ilunocitinib is the international nonproprietary name. [8]

Ilunocitinib is sold under the brand name Zenrelia. [1] [3]

References

  1. 1 2 3 4 5 6 "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-12-20]". Health Canada . 20 December 2024. Retrieved 21 December 2024. Text was copied from this source. Reproduction is authorized provided the source is acknowledged.
  2. ↑ "Zenrelia". U.S. Food and Drug Administration (FDA). Retrieved 21 December 2024.
  3. 1 2 3 4 5 "Zenrelia (ilunocitinib tablets) Dogs". U.S. Food and Drug Administration (FDA). NADA 141-585.
  4. ↑ "FDA Approves New Treatment for Allergic Skin Conditions in Dogs". U.S. Food and Drug Administration (FDA). 19 September 2024. Archived from the original on 20 September 2024. Retrieved 21 December 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  5. 1 2 "Dear Veterinarian Letter regarding important safety information associated with the use of Zenrelia (ilunocitinib tablets) for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 20 September 2024. Retrieved 21 December 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  6. ↑ "Recent Animal Drug Approvals". U.S. Food and Drug Administration. 1 October 2024. Archived from the original on 12 September 2019. Retrieved 21 December 2024.
  7. 1 2 "Zenrelia EPAR". European Medicines Agency (EMA). 13 June 2025. Retrieved 15 June 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ↑ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl: 10665/352794 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.